A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Clinical trial NCT06158516 · TERMINATED

Trial details

NCT number: NCT06158516
Sponsor: Changhai Hospital
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Neuroendocrine Tumor

Start date: 2024-06-17
Primary completion: 2026-06-09
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.